|
Asensio Lopez MDC, Ruiz Ballester M, Bastida Nicolas FJ, Soler Pardo F, Alonso-Romero JL, Caro-Martinez C, Pascual Figal D, Lax A. miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation. Int J Mol Sci. 2025 Oct 14;26(20):10002. doi: 10.3390/ijms262010002. PubMed PMID: 41155295; PubMed Central PMCID: PMC12562630.
AÑO: 2025; IF: 4.9
|
|
Asensio-Lopez MDC, Severino P, Lax A. Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings. Front Pharmacol. 2025 Apr 28;16:1607362. doi: 10.3389/fphar.2025.1607362. eCollection 2025. No abstract available. PubMed PMID: 40356986; PubMed Central PMCID: PMC12067795.
AÑO: 2025; IF: 4.8
|
|
Asensio-Lopez M.d.C., Ruiz-Ballester M., Pascual-Oliver S., Bastida-Nicolas F.J., Sassi Y., Fuster J.J., Pascual-Figal D., Soler F., Lax A. AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury. Molecular Medicine. December 2025. 31. 10.1186/s10020-025-01242-1
AÑO: 2025; IF: 6.4
|
|
Asensio-Lopez M.d.C., Severino P., Lax A. Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings. Frontiers in Pharmacology. 2025. 16. 10.3389/fphar.2025.1607362
AÑO: 2025; IF: 4.8
|
|
Pascual-Figal D, Lax A, Asensio Lopez MC. Circulating ST2, from biomarker to pathogenic mediator. Rev Esp Cardiol (Engl Ed). 2023 Sep;76(9):672-674. doi: 10.1016/j.rec.2023.02.012. Epub 2023 Apr 19. No abstract available. English, Spanish. PubMed PMID: 37085116.
AÑO: 2023; IF: 5.9
|